WHO endorses Gilead's twice-yearly HIV prevention injection amid funding concerns
The WHO has recommended injectable lenacapavir, administered twice a year, as a new PrEP option for HIV prevention, aiming to improve adherence and expand prevention strategies globally. The guidelines also include simplified testing procedures and integration of HIV services with broader health care, emphasizing immediate implementation to combat stagnating HIV prevention efforts amid ongoing challenges.